Potential therapeutic targets and medications for arteriovenous malformations of the central nervous system

Zhensong Li1,2, Yueshan Feng1,2, Shiju Zhang1,2, Yuan Zhou1,2, Jiaxing Yu1,2, Hongqi Zhang1,2, and Tao Hong1,2*

1Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China
2International Neuroscience Institute, Beijing, China

Abstract

Arteriovenous malformations (AVMs) of the central nervous system are high-flow arteriovenous shunts that lead to considerable risks of hemorrhagic stroke and neurological deficits in young patients. Due to the complex angioarchitecture and their close anatomical relationship with the brain and spinal cord, the management of brain and spinal AVMs is challenging. Conventional invasive treatments, including microsurgery, endovascular embolization, and stereotactic radiosurgery, are associated with considerable risks and unsatisfactory efficacy. In addition, the lack of medications for AVMs represents an unmet clinical need. In recent years, the pathogenesis of AVMs has been progressively explored. The increased understanding of the mechanisms of the formation, progression, and rupture of AVMs has opened up several potential directions for AVM pharmacotherapy. In recent years, some promising drugs targeting angiogenesis, inflammation, vessel wall integrity, and the mitogen-activated protein kinase (MAPK)-extracellular receptor kinase (ERK) signaling pathway have been tested in a series of clinical investigations. In this review, we summarize the potential mechanisms, preliminary efficacy, and side effects of the candidate medications, including bevacizumab, minocycline or doxycycline, thalidomide, and trametinib, in the treatment of brain and spinal AVMs.

Keywords: Arteriovenous malformations; Therapeutic targets; Medication; Vascular integrity; Somatic mutations

1. Introduction

Arteriovenous malformations (AVMs) are high-flow angioopathies that are characterized by direct connections between arteries and veins\(^1\). Although AVM lesions have been detected in most bodily tissues, they are 20 times more likely to occur in the central nervous system (CNS), as with brain arteriovenous malformations (BAVMs) and spinal cord arteriovenous malformations (SAVMs), than in other locations\(^2\). Nearly 95% of cases of AVMs in the CNS are sporadic or single lesions, while the remaining cases are genetic AVM syndromes, such as hereditary hemorrhagic telangiectasia (HHT), capillary malformation-artersiovenous malformation (CM-AVM) syndrome, and neurofibromatosis\(^3,4\).
BAVMs have an incidence of 1.3/100,000 patient-years, while the incidence of SAVMs has been reported to be 1/100 that of BAVMs\(^5\). These lesions are a significant cause of hemorrhagic stroke in young patients. Natural history studies have shown that the annual hemorrhagic rate of an unselected BAVM cohort is 1\%–4\% and approximately 5\% for patients with a rupture history\(^{6-11}\). Considering that BAVMs are commonly observed in young patients aged 20 – 40 years, patients with BAVMs may harbor a significantly higher mortality risk than healthy populations\(^1\). Compared to BAVMs, SAVMs are characterized by a greater clinical risk\(^1\). They usually lead to neurological deficits, resulting from hemorrhage and venous hypertension of the spinal cord. The average age of onset of SAVM is 25 years, and its pre-treatment annual neurological deficit deterioration rate is over 30\%\(^1\). The largest cohort study has shown that the annual hemorrhagic rate is 10\% and the cumulative spinal hemorrhagic rate 4 years after the initial onset of symptoms is 32\%\(^1\).

Several interventional approaches, including microsurgery, endovascular embolization, and stereotactic radiotherapy, are used alone or in combination to obliterate AVM lesions. However, due to their complex angioarchitecture and their close anatomical relationship with brain or spinal cord tissue, the outcomes of current treatment strategies are unsatisfactory. It has been indicated that the complete obliteration rate in published BAVM cases was <50\%, with a permanent treatment-related neurological deficit rate of 4 – 7\%\(^1\).\(^3\).\(^5\). The invasive interventions for SAVMs are even more challenging: the permanent treatment-related clinical deterioration rate reported in literature varies between 4\% and 25\%\(^1\),\(^3\),\(^6\),\(^7\), and <40\% of patients can be cured. In addition, prospective clinical trials, such as a randomized trial of unruptured BAVMs (ARUBA), have shown that interventional therapy increases the risk of stroke or death in patients with unruptured BAVMs\(^6\). The lack of pharmacotherapy for AVMs represents a compelling unmet clinical need and has thus prompted the investigation of the use of bevacizumab to reduce the risk of hemorrhage or death in patients with unruptured BAVMs\(^6\). The preliminary results were still discouraging.

The above favorable results have prompted the investigation of the use of bevacizumab to reduce the risk of hemorrhage in CNS AVMs. However, a recently published proof-of-concept pilot study of bevacizumab in BAVMs has shown a negative result\(^1\).\(^6\). As the first clinical investigation to evaluate bevacizumab as a treatment for sporadic BAVMs, the study recruited two patients with large (Spetzler–Martin Grade IV/V) brain AVMs who denied a history of intracranial hemorrhage (ICH). The participants received 5 mg/kg of bevacizumab every 2 weeks for 12 weeks; however, the AVM volumes observed 26 and 52 weeks after the treatment did not change compared to the baseline. Although the symptoms were stable and the patients’ serum VEGF levels reduced, the results were still discouraging.
Table 1. Clinical Study of VEGF Inhibition.

<table>
<thead>
<tr>
<th>Medication</th>
<th>Target</th>
<th>Publication</th>
<th>Phase</th>
<th>Dosage</th>
<th>Duration</th>
<th>Number of cases</th>
<th>Objective</th>
<th>Result</th>
<th>Side effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bevacizumab VEGF</td>
<td>Simonds et al., 2009[36]</td>
<td>-</td>
<td>100mg, once</td>
<td>Retreatment is performed when needed</td>
<td>19</td>
<td>Evaluate the effectiveness</td>
<td>Frequency and severity of bleeding was decreased</td>
<td>Not displayed</td>
<td></td>
</tr>
<tr>
<td>Bevacizumab VEGF</td>
<td>Karnezis et al., 2012[29]</td>
<td>-</td>
<td>100mg, once to 8 times,</td>
<td>Different for each patient</td>
<td>19</td>
<td>Evaluate treatment response</td>
<td>Effectively for epistaxis and effective and lasted for 12 months</td>
<td>Not displayed</td>
<td></td>
</tr>
<tr>
<td>Bevacizumab VEGF</td>
<td>Dupuis-Girod et al., 2014[31]</td>
<td>1</td>
<td>12.5/25/50/75/100 mg, once</td>
<td>40</td>
<td>Investigate the tolerance, bioavailability and efficacy</td>
<td>This nasal spray left no detection in the serum, and shows no efficacy</td>
<td>No dose limiting toxicity within the dose range</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bevacizumab VEGF</td>
<td>Dupuis-Girod et al., 2016[32]</td>
<td>2/3*</td>
<td>25/50/75 mg</td>
<td>80</td>
<td>Evaluate the efficacy</td>
<td>Epistaxis duration has no significant difference</td>
<td>No severe Adverse events reported</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bevacizumab VEGF</td>
<td>Olsen et al., 2020[33]</td>
<td>-</td>
<td>5 mg/kg of body weight</td>
<td>6 times, for a total duration of 3 months</td>
<td>2</td>
<td>Find out treatment result</td>
<td>Effective for symptoms from the liver AVMs</td>
<td>Vulnerable and flossy nails reported; itchy, dry skin and alopecia areata</td>
<td></td>
</tr>
<tr>
<td>Pazopanib VEGF</td>
<td>Marie et al., 2019[34]</td>
<td>-</td>
<td>50mg daily</td>
<td>12 weeks</td>
<td>7</td>
<td>demonstrate efficacy and safety</td>
<td>Decrease in epistaxis duration, &gt; 2 gm improvement in Hgb</td>
<td>Bronchitis and nausea; elevated alanine aminotransferase (considered severe)</td>
<td></td>
</tr>
</tbody>
</table>

*: Termination of Phase 3 study before its launching due to previous unbeneficial results on the recommendations of the monitoring committee,
*: Phase not mentioned in the article or belonging to any of them, ALT: Alanine aminotransferase, AVM: Arteriovenous malformation, Hgb: Hemoglobin, VEGF: Vascular endothelial growth factor

Although earlier experience of bevacizumab in the treatment of encephalodema, as an adverse effect caused by radiation in patients with brain AVMs, showed nidus obliteration after the administration of the drug, the combination of Gamma Knife limited the evaluation of the efficacy of bevacizumab in terms of accuracy[37].

In addition, the anti-VEGF effect of bevacizumab is toxic to endothelial cells, which may increase the hemorrhagic risk of AVMs, as reported by Tanvetyanon et al., and the side effects of the drug, such as thrombotic events, severe hypertension, and cardiac failure, are also significant[38].

2.2. Inflammation

Similar to angiogenesis, the vital role of inflammation in the progression of brain AVMs has been recognized ever since early pathological studies were performed[39]. In both human and mouse AVM samples, an upregulation in the expression of a series of inflammatory factors was observed. Furthermore, the infiltration of monocytes and granulocytes was also observed in surgical AVM samples.

A recently published single-cell atlas of BAVMs has established the contribution of inflammatory processes to BAVM rupture[40].

Among various inflammatory factors, matrix metalloproteinase-9 (MMP-9) is the most concerned molecule because its activation has been shown to be associated with vascular wall instability[41,42]. The matrix metalloproteinase inhibitor doxycycline has been evaluated for abdominal aortic aneurysm treatment[43]. Since the previous studies have shown that the expression of MMP-9 is significantly upregulated in BAVM samples, theoretically, the inhibition of MMP-9 may stabilize the vasculature of AVMs and reduce the hemorrhagic risk[44].

The earliest clinical investigation of MMP-9 in AVMs was conducted by Hashimoto et al. in 2005[45], in which 10 patients received doxycycline (100 mg, twice a day) for 1 week before BAVM resection and four patients received placebo. Compared to placebo-treated AVMs, doxycycline-treated AVMs showed a trend of reduced MMP-9 expression[45]. In 2008, Frenzel et al. published the results of a pilot study of minocycline and doxycycline in the treatment
of BAVMs\textsuperscript{46}. Twelve BAVM patients were recruited and were treated with minocycline or doxycycline (200 mg/day) for up to 2 years. The results of their follow-up suggested that patients with BAVMs are able to tolerate minocycline and doxycycline well; however, their results failed to show any trend toward potential patient benefit because one BAVM ruptured during the treatment. In another study, Burrows \textit{et al.} used marimastat, another MMP inhibitor, for the treatment of a young girl with multiple AVMs involving the upper extremities\textsuperscript{47}. Following the treatment with marimastat, the young girl experienced pain relief, and there was healing of bony destruction; however, newly formed AVMs were observed during the treatment. Therefore, although the rationale of anti-inflammation therapy is justified and commended, there has been no solid evidence showing that it may benefit patients with AVMs of the CNS. Table 2 shows different clinical studies of MMP inhibitors according to timeline.

### 2.3. Vascular integrity

The results of emerging studies have suggested that BAVM rupture is associated with a maldeveloped vascular wall structure\textsuperscript{48–50}. Compared with healthy cerebral vasculature, the BAVMs in both human and mouse models are characterized by abnormal vessels lacking mural cells (vascular smooth muscle cells and pericytes), which are similar to engorged and expanded capillaries\textsuperscript{49}. With insights into the physiological function of mural cells, the above pathological features of AVMs may represent impaired vascular integrity and a tendency for rupture. As expected, clinical pathological investigations have indicated that these thin-walled vessels are the source of microhemorrhage and subsequent inflammatory reaction, which has been shown to be correlated with ICH in BAVMs\textsuperscript{51}. Therefore, the repair of vascular mural cells has been considered a potential treatment strategy for BAVMs in recent years\textsuperscript{48,50}.

This hypothesis was mainly inspired by the efficacy of thalidomide for patients with HHT, as shown in a study where the platelet-derived growth factor-B/platelet-derived growth factor receptor (PDGF-B/PDGF-R) signaling pathway was upregulated and mural cells were recruited following thalidomide intervention in mice\textsuperscript{52}. A series of clinical investigations have confirmed that oral thalidomide could significantly protect against epistaxis and gastrointestinal hemorrhage caused by telangiectasias\textsuperscript{53,54}. From pathological and genetic points of view, telangiectasias and AVMs are distinct lesions. However, the key pathological feature of telangiectasia is also the expansion of capillaries with pericycle coverage reduction. The previous studies have revealed that thalidomide can enhance pericycle coverage in telangiectasia by enhancing the expression of PDGF-B in endothelial cells\textsuperscript{52}. The PDGF-B/PDGF-R signaling pathway plays a key role in recruiting mural cells. During angiogenesis, endothelial cell paracrine PDGF-B and its receptor PDGF-R are mainly expressed in the precursors of pericytes and vascular smooth muscle cells\textsuperscript{52}. Although no compelling studies have found an impairment of the PDGF-B/PDGFR signaling pathway in sporadic AVMs, the above findings still indicate that thalidomide may be a promising candidate for the pharmacological treatment of brain and spinal AVMs. To the best of our knowledge, thalidomide has not been investigated in patients with brain or spinal AVMs. A major concern about the use of thalidomide in AVM patients is its rare and frequent toxicities, such as teratogenicity and peripheral neuropathy\textsuperscript{55}. In addition, a relapse of epistaxis

<table>
<thead>
<tr>
<th>Medication</th>
<th>Target</th>
<th>Publication</th>
<th>Phase</th>
<th>Dosage</th>
<th>Duration</th>
<th>Number of cases</th>
<th>Objective</th>
<th>Result</th>
<th>Side effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doxycycline</td>
<td>MMP-9</td>
<td>Hashimoto \textit{et al.}, 2005\textsuperscript{22}</td>
<td>-</td>
<td>100 mg, twice a day</td>
<td>One week</td>
<td>14</td>
<td>Investigate doxycycline effect for MMP-9</td>
<td>Decreased MMP-9 in AVM tissues</td>
<td>Not displayed</td>
</tr>
<tr>
<td>Minocycline</td>
<td>MMP-9</td>
<td>Frenzel \textit{et al.}, 2008\textsuperscript{41}</td>
<td>-</td>
<td>100 mg, twice a day</td>
<td>Two years</td>
<td>26</td>
<td>Evaluate feasibility</td>
<td>Similar adverse event rates were recorded</td>
<td>Dose-limiting intolerance occurred in 31% minocycline and 23% doxycycline patients</td>
</tr>
<tr>
<td>Marimastat</td>
<td>MMP</td>
<td>Burrows \textit{et al.}, 2009\textsuperscript{47}</td>
<td>-</td>
<td>30–120 mg, 100 mg, daily</td>
<td>Several years</td>
<td>1</td>
<td>Case report of treatment effect</td>
<td>Pain relieved, and recurrence of symptoms appeared</td>
<td>No adverse effects</td>
</tr>
<tr>
<td>Doxycycline</td>
<td>MMP-9</td>
<td>Lindeman \textit{et al.}, 2009\textsuperscript{43}</td>
<td>-</td>
<td>50/100/300 mg, daily</td>
<td>2 weeks</td>
<td>60</td>
<td>Evaluate vascular inflammation level</td>
<td>Short and selective inhibitory effect on inflammation was recorded</td>
<td>Not displayed</td>
</tr>
</tbody>
</table>

<sup>\textsuperscript{-} Phase not mentioned in the article or belonging to any of them, AVM: Arteriovenous malformation, MMP-9: Matrix metalloproteinase-9</sup>
has been observed following a cessation of treatment with thalidomide in HTT patients; therefore, the potential antihemorrhagic efficacy of thalidomide for AVMs may be nullified with the withdrawal of the drug. Table 3 shows different clinical studies of thalidomide according to timeline.

2.4. Mutation of mitogen-activated protein kinase (MAPK) pathway genes

The hereditary mechanism and the causative genes of AVM syndromes, such as HHT and CM-AVM syndrome, have been extensively investigated. However, the genetic basis of sporadic AVMs was not discovered until 2017, when Couto et al. performed whole-exome sequencing on 10 extracranial AVM samples and found that 7 (70%) of them harbored mutations in mitogen-activated protein kinase kinase 1 (MAP2K1) in endothelial cells. The results were confirmed by droplet digital polymerase chain reaction (PCR). In 2018, Nikolaev et al. demonstrated somatic activating KRAS mutations in BAVM samples and localized the mutant gene in endothelial cells. Through ultra-deep next-generation sequencing of a panel of 422 common tumor genes and droplet digital PCR, our group also demonstrated a high prevalence (87.1%) of KRAS/BRAF somatic mutations in sporadic brain and spinal AVMs. Since Kirsten rat sarcoma viral oncogene homologue (KRAS), proto-oncogene B-Raf and v-Raf murine sarcoma viral oncogene homologue B (BRAF), and MAP2K1 all belong to the MAPK signaling pathway, these studies have confirmed that there is genetic homogeneity in sporadic AVMs. Figure 1 presents the KRAS/BRAF signaling pathway and MEK1 (also known as MAP2K1) inhibitor in sporadic AVMs.

Two important animal model studies have answered the question of whether the somatic mutations in MAPK pathway genes are the cause of AVM formation or the consequence of AVM progression. They have found that both heterozygous KRAS G12D mutation and the overexpression of KRAS G12V in cerebral endothelial cells can cause BAVM lesions in mice. More importantly, these studies have verified that the activation of ERK-MAPK pathway, rather than phosphoinositide 3-kinase (PI3K)-MAPK, is the cause of AVM formation, and trametinib, an MAP2K1 inhibitor, can restrict the development and progression of AVM in animal models. Therefore, a genotype-guided targeted treatment for sporadic AVMs with activating mutations of ERK-MAPK pathway genes has been developed, and trametinib has been used to treat four patients with extracranial AVMs thus far. Although the outcomes in these studies were measured in a crude and relatively subjective manner, the results still indicated that trametinib is effective in reducing the size of and blood flow to AVM lesions. Table 4 shows different clinical studies of trametinib according to timeline.

Clinical trials of trametinib in patients with BAVMs or SAVMs have not been reported in literature. One limitation is that genotype-guided management relies on the availability of AVM samples; however, a biopsy of brain or spinal AVMs is risky and not feasible in most cases. As a countermeasure, cell-free DNA sequencing may be a promising strategy, although its sensitivity is currently not favorable. Cooke et al. have revealed the findings of an endovascular biopsy, using coils to collect endothelial cells of BAVMs. The biopsy was inventively designed and is practical for patients with refractory BAVM lesions.

The results of recent clinical and animal model studies have suggested that trametinib may be a promising treatment option for AVMs.

Table 3. Clinical Study of Thalidomide.

<table>
<thead>
<tr>
<th>Medication</th>
<th>Target</th>
<th>Publication</th>
<th>Phase</th>
<th>Dosage</th>
<th>Duration</th>
<th>Number of cases</th>
<th>Objective</th>
<th>Result</th>
<th>Side effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thalidomide</td>
<td>PDGF-B</td>
<td>Lebrin et al., 2010</td>
<td>–</td>
<td>100 mg, once a day</td>
<td>One month</td>
<td>7</td>
<td>Report the drug effect</td>
<td>6/7 patients acquired a lower rate of epistaxis frequency</td>
<td>Minor side effects: mild constipation, loss of libido, drowsiness and lethargy</td>
</tr>
<tr>
<td>Thalidomide</td>
<td>VEGF</td>
<td>Ge et al., 2011</td>
<td>–</td>
<td>100 mg, daily</td>
<td>4 months</td>
<td>55</td>
<td>Investigate the long-term efficacy and safety</td>
<td>Thalidomide group showed effective response; VEGF were significantly reduced</td>
<td>No severe side effects while mild side effects were common</td>
</tr>
<tr>
<td>Thalidomide</td>
<td>Controversial</td>
<td>Invernizzi et al., 2015</td>
<td>2</td>
<td>50-200 mg, daily</td>
<td>8-12 additional weeks after response</td>
<td>31</td>
<td>Study efficacy and safety</td>
<td>All patients' epistaxis symptoms were decreased</td>
<td>Non-serious effects, one patient died considering unrelated</td>
</tr>
</tbody>
</table>

-- Phase not mentioned in the article or belonging to any of them, PDGF-B: Platelet-derived growth factor-B, VEGF: Vascular endothelial growth factor
candidate for the treatment of brain and spinal AVMs\textsuperscript{60,66}. However, in a report of a patient with Cobb syndrome, we noticed that although the extracranial AVM had shrunk after trametinib treatment, the blood flow to and lesion size of the intracranial AVM had not changed\textsuperscript{61}. The concern about the sensitivity of brain and spinal AVMs to trametinib treatment is not groundless considering that AVMs of the CNS are quite stable compared with their extracranial counterparts\textsuperscript{67}. In addition, considering the longer survival rate of patients with AVMs than that of patients with malignant tumors, the side effects of antineoplastic drugs should not be neglected.

3. Perspectives and conclusion

Based on the understanding of the pathogenesis and pathophysiological mechanisms of AVMs, a series of drugs targeting angiogenesis, inflammation, vascular integrity, and MAPK-ERK pathway signaling have been assumed to be effective against the disease. Unfortunately, emerging evidence has revealed that the prospects of these drugs may not be as optimistic as expected. Bevacizumab used to be the most anticipated candidate; however, there was no change observed in the structure of BAVMs in patients who received the drug. MMP-9 inhibitors were thought to

---

**Figure 1.** KRAS/BRAF signaling pathway and MEK1 inhibitor in sporadic arteriovenous malformations. Trametinib acts as a pathway inhibitor that blocks downstream responses.

**Table 4. Clinical Study of Trametinib.**

<table>
<thead>
<tr>
<th>Medication</th>
<th>Target</th>
<th>Publication</th>
<th>Phase</th>
<th>Number of cases</th>
<th>Dosage</th>
<th>Duration</th>
<th>Objective</th>
<th>Result</th>
<th>Side effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trametinib</td>
<td>MEK inhibitor</td>
<td>Lekwuttikarn \textit{et al.}, 2019\textsuperscript{63}</td>
<td>-</td>
<td>1</td>
<td>0.5mg, daily to twice a day</td>
<td>6 months</td>
<td>Report clinical effect</td>
<td>Found a reduced size and lighter color</td>
<td>A mild acneiform eruption</td>
</tr>
<tr>
<td>Trametinib</td>
<td>MEK inhibitor</td>
<td>Edwards \textit{et al.} 2020\textsuperscript{61}</td>
<td>-</td>
<td>1</td>
<td>0.025 mg/kg, daily</td>
<td>6 months</td>
<td>Report clinical effect</td>
<td>75% reduction in arterial blood flow from the AVM</td>
<td>Not displayed</td>
</tr>
<tr>
<td>Trametinib</td>
<td>MEK inhibitor</td>
<td>Samkari \textit{et al.}, 2021\textsuperscript{64}</td>
<td>-</td>
<td>1</td>
<td>Not mentioned</td>
<td>6 months</td>
<td>Report clinical effect</td>
<td>No more bleeding reported, found the AVM smaller and lighter in color</td>
<td>Not displayed</td>
</tr>
<tr>
<td>Trametinib</td>
<td>MEK inhibitor</td>
<td>Nicholson \textit{et al.}, 2022\textsuperscript{62}</td>
<td>-</td>
<td>1</td>
<td>2.0-0.5mg, daily</td>
<td>Over a year, 0.5mg daily now</td>
<td>Report clinical effect</td>
<td>Shunting improved and AVM got more stable structures</td>
<td>Cutaneous toxicity</td>
</tr>
</tbody>
</table>

\textsuperscript{--}: Phase not mentioned in the article or belonging to any of them, AVM: Arteriovenous malformation, MEK: Mitogen-activated protein kinase kinase
be able to stabilize the vasculature of AVMs, but it has been reported that patients under MMP inhibition treatment still carry a risk for BAVM rupture. The use of thalidomide, on the other hand, may enhance the integrity of AVM vessels and reduce the hemorrhagic risk, but its noticeable toxicities undoubtedly restrict its use. In a patient with Cobb syndrome, trametinib has shown to be effective for the treatment of extracranial AVMs but not spinal cord AVMs, indicating that AVMs of the CNS may not be sensitive to trametinib, just as the natural course of brain and spinal AVMs is more stable than that of extracranial AVMs. The safety of trametinib should also be assessed for patients without malignant diseases. Although some of the findings have not been fully translated into clinical studies, they are still of interest. The Notch signaling pathway has been the subject of a number of research, some of which have revealed that it is activated in surgical specimens and its upregulation alters the vascular structure, as shown in a mouse model of Notch-mediated AVMs. The previous studies have also shown that members of the Notch signaling pathway and their downstream molecules are associated with angiogenesis and hypoxia upregulates Notch signaling, thus causing inflammation and vascular remodeling, whose subsequent reactions are related to the formation of AVM. Notch is associated with multiple pathways of conduction but its mechanism in AVM has not been fully elucidated. The study of Notch inhibitors is challenging due to their wide range of interactions. Unfortunately, clinical studies are not yet in sight. As of now, we know that Notch inhibitor causes dose-dependent inhibition of endothelial cell migration and network formation in vitro. A Smad family member 4 (Smad4)-inducible, endothelial cell-specific knockout (Smad4-iECKO) mouse model has established that angiopoietin-2 inhibition rescues AVM formation, which is indeed an inspiring finding.

We speculate that the relatively stable natural course of CNS AVMs compared to that of malignant tumors presents a challenge in the development of pharmacotherapy for AVMs. The evidence on the growth of AVMs in the brain or spinal cord is anecdotal, and the existence of arteriovenous shunts with expanded vascular caliber mainly relies on arterial blood flow rather than aberrant signaling pathways, as is the case with neoplasms. Therefore, pharmacotherapy strategies for malignant tumors may not be appropriate for AVMs. Given the applicability of the genetic-based mouse model of sporadic AVMs, we believe that further studies should be devoted to assessing the difference in expression between malformed vessels and intact vasculature. The development of specific markers may help distinguish AVM vessels from normal vessels, which may facilitate precise delivery of drugs for AVMs. In conclusion, invasive treatments will likely continue to be the sole management strategy for AVMs for a considerable amount of time, and the lack of pharmacotherapy for brain and spinal AVMs represents an unmet clinical need and, without a doubt, a significant potential for innovative research.

Acknowledgments
None.

Funding
None.

Conflict of interest
The authors declare that they have no competing interests.

Author contributions
Conceptualization: Zhengsong Li, Jiaxing Yu, and Tao Hong
Supervision: Tao Hong and Hongqi Zhang
Writing – original draft: Zhengsong Li, Yueshan Feng, Shiju Zhang, Yuan Zhou, and Jiaxing Yu
Writing – review & editing: Zhengsong Li

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Availability of data
Not applicable.

References
https://doi.org/10.3171/jns.1983.59.3.0471

https://doi.org/10.1016/S0140-6736(13)62302-8

https://doi.org/10.3171/jns.1988.68.3.0352

https://doi.org/10.1161/STR.0000000000000134

https://doi.org/10.1093/brain/124.10.1900

https://doi.org/10.1227/01. NEU.0000330401.82582.5E

https://doi.org/10.1212/WNL.0000000000000688

https://doi.org/10.1161/01. STR.31.6.1307

https://doi.org/10.1093/brain/aws153

https://doi.org/10.1056/NEJMra1607407

https://doi.org/10.3171/jns.2004.100.5.0810

https://doi.org/10.3171/2013.4.spine12732

https://doi.org/10.1161/STROKEAHA.114.006087

https://doi.org/10.1038/nrdp.2015.8

https://doi.org/10.1093/brain/awt180

https://doi.org/10.1126/science.284.5422.1994

https://doi.org/10.1016/S0140-6736(15)01088-0

https://doi.org/10.1213/01. NEU.0000175725.53372.69

https://doi.org/10.1159/000090526

https://doi.org/10.1016/j.jocn.2010.04.028

https://doi.org/10.1016/j.devcel.2012.02.005

https://doi.org/10.1182/blood-2010-02-270819

https://doi.org/10.1007/s10456-004-8272-2

https://doi.org/10.1016/S1470-2045(10)70232-1

https://doi.org/10.1161/CIRCULATIONAHA.108.806505

https://doi.org/10.1186/s13023-020-01583-6

https://doi.org/10.4161/mabs.28025

https://doi.org/10.1001/jama.2016.11387

https://doi.org/10.1186/s13023-020-01583-6

https://doi.org/10.1161/STROKEAHA.111.647982

https://doi.org/10.1007/s10456-018-9646-1

https://doi.org/10.1136/bmjno-2020-000114

https://doi.org/10.3171/2012.1.JNS111627

https://doi.org/10.1097/JTO.0b013e318195a642

https://doi.org/10.1038/jcbfm.2014.179

https://doi.org/10.1126/science.abi7377

https://doi.org/10.1161/01.RES.0000013290.12884.A3

https://doi.org/10.1161/res.90.3.251

https://doi.org/10.1161/CIRCULATIONAHA.108.806505

https://doi.org/10.1161/01.STR.0000061888.71524.DF

https://doi.org/10.1186/1471-2377-5-1

https://doi.org/10.1159/000113733

https://doi.org/10.1097/SCS.0b013e3181927f1e


Targets and medications for AVM of CNS

   https://doi.org/10.1093/brain/awp246

   https://doi.org/10.1038/nature10144

   https://doi.org/10.1016/j.neuron.2015.06.038

   https://doi.org/10.1016/j.devcel.2005.09.010

   https://doi.org/10.1016/j.jvs.2013.02.240

   https://doi.org/10.1016/j.yexcr.2013.01.010

   https://doi.org/10.1155/2014/318714

   https://doi.org/10.1038/s41598-018-36628-1

   https://doi.org/10.1161/CIRCULATIONAHA.118.036952